CN113577072A - Cocktail anesthetic analgesic injection and preparation method and application thereof - Google Patents
Cocktail anesthetic analgesic injection and preparation method and application thereof Download PDFInfo
- Publication number
- CN113577072A CN113577072A CN202111084167.7A CN202111084167A CN113577072A CN 113577072 A CN113577072 A CN 113577072A CN 202111084167 A CN202111084167 A CN 202111084167A CN 113577072 A CN113577072 A CN 113577072A
- Authority
- CN
- China
- Prior art keywords
- anesthetic
- cocktail
- mixing
- injection
- lidocaine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003444 anaesthetic effect Effects 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 238000002347 injection Methods 0.000 title claims abstract description 37
- 239000007924 injection Substances 0.000 title claims abstract description 37
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 28
- 238000002156 mixing Methods 0.000 claims abstract description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 21
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960004194 lidocaine Drugs 0.000 claims abstract description 18
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims abstract description 17
- 206010002091 Anaesthesia Diseases 0.000 claims abstract description 17
- 230000037005 anaesthesia Effects 0.000 claims abstract description 17
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims abstract description 16
- 229960001813 ropivacaine hydrochloride Drugs 0.000 claims abstract description 16
- 229930182837 (R)-adrenaline Natural products 0.000 claims abstract description 15
- 229960005139 epinephrine Drugs 0.000 claims abstract description 15
- 230000001954 sterilising effect Effects 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims description 31
- 239000002504 physiological saline solution Substances 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 230000003416 augmentation Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000003601 intercostal effect Effects 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 210000000062 pectoralis major Anatomy 0.000 claims description 6
- 210000000989 pectoralis minor Anatomy 0.000 claims description 6
- 210000000038 chest Anatomy 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 230000002411 adverse Effects 0.000 abstract description 3
- 238000010979 pH adjustment Methods 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 25
- 238000001356 surgical procedure Methods 0.000 description 13
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 9
- 210000000481 breast Anatomy 0.000 description 9
- 230000036592 analgesia Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940073869 ropivacaine injection Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Abstract
The invention discloses a cocktail anesthesia analgesic injection and a preparation method and application thereof; the prepared cocktail anesthetic analgesic injection comprises an anesthetic A and an anesthetic B, wherein the anesthetic A is formed by mixing 200-250ml of normal saline, 180-220mg of lidocaine and 0.20-0.28mg of epinephrine, and the anesthetic B is formed by mixing 40-60ml of normal saline and 100-120mg of ropivacaine hydrochloride; the preparation method comprises the following steps: respectively and fully mixing the components in the anesthetic A and the anesthetic B, and then carrying out steps of pH adjustment, sterilization and the like to prepare the corresponding anesthetic A and the anesthetic B; and the anesthetic A and the anesthetic B are applied to chest anesthesia, so that adverse effects such as complications and the like generated in and after operations of patients can be reduced, and the operation safety is improved.
Description
Technical Field
The invention relates to the technical field of anesthesia and analgesia, in particular to cocktail anesthesia and analgesia injection and a preparation method and application thereof.
Background
The postoperative analgesia method of the whole hip and the whole knee is more, and literature reports that local injection of an analgesia mixture (also called cocktail therapy) around the joint can obtain good analgesia effect.
Clinical postoperative pain methods mainly comprise oral administration, intramuscular or intravenous injection of analgesics, anesthesia analgesic pumps, peripheral nerve block, epidural external tubes, continuous ice compress, intra-articular anesthesia analgesic perfusion, intra-articular local anesthesia analgesic injection and the like, but oral administration, intramuscular or intravenous injection of the anesthesia analgesics can cause respiratory depression, lethargy, nausea, vomiting and other complications; peripheral nerve block and epidural catheter have the risks of hematoma, infection, urinary retention, nerve injury and the like, and meanwhile, the application of postoperative anticoagulant drugs is limited, and the infection risk can be increased by continuous intra-articular anesthesia analgesic perfusion.
The mixed anesthesia analgesic drug injected around the joint has good postoperative analgesic effect and less adverse reaction. The combination of injection has various schemes, and local anesthetic is used as main ingredient and can be combined with morphine, hormone, adrenaline, etc. The principle is to eliminate the stimulation and conduction of the operation incision to the pain so as to achieve the purpose of preventing and controlling the postoperative pain. S te i n et al report that significant analgesic effects can be achieved after small doses of morphine are injected into the knee joint cavity after arthroscopic surgery. Ker r r and other research results show that peri-articular ropivacaine injection after joint replacement has obvious and safe analgesic effect. The adrenalin can delay the local absorption speed of the medicine, prolong the action time and reduce the adverse reaction of the whole body. The cocktail type analgesic mixture injected around the joint can obviously relieve early resting pain and activity pain of patients after total hip and total knee operations, obviously advance the time of actively moving straight legs after the operations, obviously increase the activity of knee joints at the early stages after the operations, and have no obvious adverse reaction and incision complications.
On the other hand, few studies have been made on whether the cocktail therapy is effective in anesthesia and analgesia for patients during breast augmentation surgery.
Disclosure of Invention
The invention aims to provide a cocktail anesthesia analgesic injection and a preparation method and application thereof; by injecting the narcotic analgesic around the joint of the patient with breast augmentation, adverse effects such as complications generated in and after operation of the patient are reduced, and the operation safety is improved.
The first purpose of the invention is realized by the following technical scheme:
the cocktail anesthetic analgesic injection comprises an anesthetic A and an anesthetic B, wherein the anesthetic A is prepared by mixing 200-250ml of normal saline, 180-220mg of lidocaine and 0.20-0.28mg of epinephrine, and the anesthetic B is prepared by mixing 40-60ml of normal saline and 100-120mg of ropivacaine hydrochloride.
Preferably, the anesthetic A is formed by mixing 200ml of normal saline, 200mg of lidocaine and 0.25mg of epinephrine, and the anesthetic B is formed by mixing 50ml of normal saline and 100mg of ropivacaine hydrochloride.
The second purpose of the invention is to provide a preparation method of cocktail anesthesia analgesic injection, which is used for preparing cocktail anesthesia analgesic injection,
the preparation process of the anesthetic A is as follows: uniformly mixing 200-250ml of normal saline, 180-220mg of lidocaine and 0.20-0.28mg of epinephrine, adding a pH regulator, regulating the pH to 4.5-5.5, adding activated carbon for needles according to 0.06-0.08% (g/ml), stirring and filtering, and sterilizing the filtrate to obtain the anesthetic A;
the preparation process of the anesthetic B is as follows: uniformly mixing 40-60ml of physiological saline and 100-120mg of ropivacaine hydrochloride, adding a pH regulator, regulating the pH to 4.5-5.5, and sterilizing the uniformly mixed solution to obtain an anesthetic B;
the preparation process of the anesthetic A and the preparation process of the anesthetic B are both carried out in a nitrogen saturation environment.
Preferably, when the normal saline, the lidocaine and the epinephrine are uniformly mixed, the normal saline, the lidocaine and the epinephrine are uniformly mixed by stirring, the stirring time is 15-25min, the stirring speed is 1000-1200r/min, and the temperature is 50-60 ℃ when the normal saline, the lidocaine and the epinephrine are uniformly mixed;
when the physiological saline and the ropivacaine hydrochloride are uniformly mixed, the physiological saline and the ropivacaine hydrochloride are uniformly mixed by stirring, the stirring time is 5-15min, the stirring speed is 800-.
Preferably, the preparation process of the anesthetic A has the filter diameter of less than 0.5 micron when the anesthetic A is filtered.
The third purpose of the invention is to provide the application of the cocktail anesthetic analgesic injection in preparing the chest anesthetic during the breast augmentation surgery.
Preferably, before chest anesthesia, the anesthetic A100ml is injected between the pectoralis major and pectoralis minor on both sides of the patient; secondly, anesthetic B20ml is injected into the third flat intercostals, the position of the anterior axillary line and the position between the pectoralis major and the pectoralis minor on both sides of the patient, and finally anesthetic B5ml is injected into the sixth flat intercostals, the position of the anterior axillary line and the position between the lower edges of the ribs on both sides of the patient.
The invention has the beneficial effects that:
in the breast augmentation surgery, the cocktail anesthetic analgesic injection is locally injected around the joint, so that adverse effects such as toxic and side effects and complications generated in the surgery and after the surgery of a patient can be greatly reduced, and the anesthetic injection does not need to be additionally added; the injection prepared by the preparation method has the advantages of uniform mixing, stable components, quick response, long action time and the like.
Detailed Description
The technical solution of the present invention is further described in detail with reference to the following examples, but the scope of the present invention is not limited to the following.
First, examples and comparative examples
Example 1
The preparation process of the anesthetic A is as follows: uniformly mixing 200ml of normal saline, 220mg of lidocaine and 0.20mg of epinephrine, adding a pH regulator, regulating the pH to 4.5, adding activated carbon for injection according to 0.06(g/ml), stirring and filtering, and sterilizing the filtrate to obtain an anesthetic A; in the process of uniformly mixing, uniformly mixing at 50 ℃ for 15min at the speed of 1000 r/min; the filter diameter is less than 0.5 micron during filtering;
the preparation process of the anesthetic B is as follows: uniformly mixing 40ml of physiological saline and 120mg of ropivacaine hydrochloride, adding a pH regulator, regulating the pH to 4.5, and then sterilizing the uniformly mixed solution to obtain an anesthetic B; uniformly mixing by stirring, wherein the mixing temperature is 50 ℃, the stirring time is 5min, and the stirring speed is 1000 r/min;
the preparation process of the anesthetic A and the preparation process of the anesthetic B are both carried out in a nitrogen saturation environment.
Example 2
The preparation process of the anesthetic A is as follows: mixing 250ml normal saline, 180mg lidocaine and 0.28mg adrenaline, adding pH regulator, regulating pH to 5.5, adding active carbon for injection according to 0.08(g/ml), stirring, filtering, and sterilizing the filtrate to obtain anesthetic A; in the process of uniformly mixing, uniformly mixing at 60 ℃ for 25min at the stirring speed of 1200 r/min; the filter diameter is less than 0.5 micron during filtering;
the preparation process of the anesthetic B is as follows: uniformly mixing 60ml of physiological saline and 100mg of ropivacaine hydrochloride, adding a pH regulator, regulating the pH to 5.5, and then sterilizing the uniformly mixed solution to obtain an anesthetic B; uniformly mixing by stirring, wherein the mixing temperature is 60 ℃, the stirring time is 15min, and the stirring speed is 8000 r/min;
the preparation process of the anesthetic A and the preparation process of the anesthetic B are both carried out in a nitrogen saturation environment.
Example 3
The preparation process of the anesthetic A is as follows: uniformly mixing 225ml of normal saline, 200mg of lidocaine and 0.24mg of epinephrine, adding a pH regulator, regulating the pH to 5, adding activated carbon for injection according to 0.07(g/ml), stirring, filtering, and sterilizing the filtrate to obtain an anesthetic A; in the process of uniformly mixing, uniformly mixing at 55 ℃ for 20min at the speed of 1100 r/min; the filter diameter is less than 0.5 micron during filtering;
the preparation process of the anesthetic B is as follows: uniformly mixing 50ml of physiological saline and 110mg of ropivacaine hydrochloride, adding a pH regulator, regulating the pH to 5.5, and then sterilizing the uniformly mixed solution to obtain an anesthetic B; uniformly mixing by stirring, wherein the mixing temperature is 60 ℃, the stirring time is 13min, and the stirring speed is 1000 r/min;
the preparation process of the anesthetic A and the preparation process of the anesthetic B are both carried out in a nitrogen saturation environment.
Example 4
The preparation process of the anesthetic A is as follows: mixing 200ml normal saline, 200mg lidocaine and 0.25mg adrenaline, adding pH regulator, regulating pH to 5, adding active carbon for injection according to 0.07(g/ml), stirring, filtering, and sterilizing the filtrate to obtain anesthetic A; in the process of uniformly mixing, uniformly mixing at 55 ℃ for 20min at the speed of 1100 r/min; the filter diameter is less than 0.5 micron during filtering;
the preparation process of the anesthetic B is as follows: uniformly mixing 50ml of physiological saline and 100mg of ropivacaine hydrochloride, adding a pH regulator, regulating the pH to 5.5, and then sterilizing the uniformly mixed solution to obtain an anesthetic B; uniformly mixing by stirring, wherein the mixing temperature is 55 ℃, the stirring time is 10min, and the stirring speed is 1000 r/min;
the preparation process of the anesthetic A and the preparation process of the anesthetic B are both carried out in a nitrogen saturation environment.
Example 5
Preparation of anesthetic a: mixing 200ml normal saline, 200mg lidocaine and 0.25mg adrenaline to obtain anesthetic A;
preparing an anesthetic B: mixing 50ml of physiological saline and 100mg of ropivacaine hydrochloride to obtain the anesthetic B.
The analgesic effect and the safety and effectiveness of the injection are clinically researched.
Selecting 50 patients with breast augmentation surgery, randomly selecting 10 patients with the anesthetic analgesic injection prepared in each group of examples for injection, and specifically, before the breast augmentation surgery, injecting anesthetic A100ml between pectoralis major muscles and pectoralis minor muscles on both sides of the patients; secondly, anesthetic B20ml is injected into the third flat intercostals, the position of the anterior axillary line and the position between the pectoralis major and the pectoralis minor on both sides of the patient, and finally anesthetic B5ml is injected into the sixth flat intercostals, the position of the anterior axillary line and the position between the lower edges of the ribs on both sides of the patient. The specific conditions are shown in the table:
the frequent determination method of onset time and action in the above table is: stimulating the skin of a patient by using a blunt instrument such as a needle or scissors, and if the patient does not feel painful, indicating that the anesthetic takes effect, wherein the time for taking effect is the moment; the pain sensation of the patient is continuously observed during and after the operation until the patient has pain sensation, wherein the time of the drug failure is the drug acting time, and the difference between the drug failure time and the drug acting time is the drug acting time.
From the table, it can be seen that: the injection prepared in the embodiment 1-5 has fast effect time and long action time in the breast augmentation surgery process, can meet the anesthesia and analgesia requirements of patients before and after the breast augmentation surgery only by injecting the injection once before the surgery, does not generate any complication after the surgery, and has relatively high safety. In addition, the injection medicine prepared according to the preparation method of the embodiment 1-4 has the best effect, has no adverse reaction and any complication in the clinical test process, has extremely high safety, and can be widely applied to breast augmentation surgery; the injection in example 5 is not prepared according to the preparation method of the present invention, and the purity, solubility and stability of the prepared injection are slightly poor, and although a certain effect is obtained in the aspect of long duration of anesthesia, 3% of patients have mild adverse reactions and need to be improved.
The foregoing is merely a preferred embodiment of the invention, it is to be understood that the invention is not limited to the forms disclosed herein, but is not intended to be exhaustive or to limit the invention to other embodiments, and to various other combinations, modifications, and environments and may be modified within the scope of the inventive concept as expressed herein, by the teachings or the skill or knowledge of the relevant art. And that modifications and variations may be effected by those skilled in the art without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (7)
1. The cocktail anesthetic analgesic injection is characterized by comprising an anesthetic A and an anesthetic B, wherein the anesthetic A is prepared by mixing 200-60 ml of physiological saline, 180-220mg of lidocaine and 0.20-0.28mg of epinephrine, and the anesthetic B is prepared by mixing 40-60ml of physiological saline and 100-120mg of ropivacaine hydrochloride.
2. The cocktail anesthetic-containing analgesic injection as claimed in claim 1, wherein the anesthetic a is prepared by mixing 200ml normal saline, 200mg lidocaine and 0.25mg epinephrine, and the anesthetic B is prepared by mixing 50ml normal saline and 100mg ropivacaine hydrochloride.
3. A method for preparing a cocktail anesthetic analgesic injection, which is used for preparing the cocktail anesthetic analgesic injection of claim 1,
the preparation process of the anesthetic A is as follows: uniformly mixing 200-250ml of normal saline, 180-220mg of lidocaine and 0.20-0.28mg of epinephrine, adding a pH regulator, regulating the pH to 4.5-5.5, adding activated carbon for needles according to 0.06-0.08% (g/ml), stirring and filtering, and sterilizing the filtrate to obtain the anesthetic A;
the preparation process of the anesthetic B is as follows: uniformly mixing 40-60ml of physiological saline and 100-120mg of ropivacaine hydrochloride, adding a pH regulator, regulating the pH to 4.5-5.5, and sterilizing the uniformly mixed solution to obtain an anesthetic B;
the preparation process of the anesthetic A and the preparation process of the anesthetic B are both carried out in a nitrogen saturation environment.
4. The preparation method of cocktail anesthetic analgesic injection according to claim 3,
when the normal saline, the lidocaine and the epinephrine are uniformly mixed, the normal saline, the lidocaine and the epinephrine are uniformly mixed by stirring, the stirring time is 15-25min, the stirring speed is 1000-1200r/min, and the temperature is 50-60 ℃ when the normal saline, the lidocaine and the epinephrine are uniformly mixed;
when the physiological saline and the ropivacaine hydrochloride are uniformly mixed, the physiological saline and the ropivacaine hydrochloride are uniformly mixed by stirring, the stirring time is 5-15min, the stirring speed is 800-.
5. The preparation method of cocktail anesthetic analgesic injection according to claim 3,
in the preparation process of the anesthetic A, the filter diameter is less than 0.5 micron during filtration.
6. The application of cocktail anesthetic analgesic injection is characterized in that the cocktail anesthetic injection is used for preparing a chest anesthetic during a chest augmentation operation.
7. The use of cocktail anesthetic analgesic injection according to claim 6 wherein prior to thoracic anesthesia, anesthetic A100ml is injected between the pectoralis major and pectoralis minor muscles on both sides of the patient; secondly, anesthetic B20ml is injected into the third flat intercostals, the position of the anterior axillary line and the position between the pectoralis major and the pectoralis minor on both sides of the patient, and finally anesthetic B5ml is injected into the sixth flat intercostals, the position of the anterior axillary line and the position between the lower edges of the ribs on both sides of the patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111084167.7A CN113577072A (en) | 2021-09-14 | 2021-09-14 | Cocktail anesthetic analgesic injection and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111084167.7A CN113577072A (en) | 2021-09-14 | 2021-09-14 | Cocktail anesthetic analgesic injection and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113577072A true CN113577072A (en) | 2021-11-02 |
Family
ID=78242057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111084167.7A Pending CN113577072A (en) | 2021-09-14 | 2021-09-14 | Cocktail anesthetic analgesic injection and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113577072A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670489A (en) * | 2012-05-10 | 2012-09-19 | 山东洁晶药业有限公司 | Ropivacaine hydrochloride sodium chloride injection and preparation method thereof |
| CN104146954A (en) * | 2014-08-29 | 2014-11-19 | 广东埃纳生医疗投资发展有限公司 | Composite local anesthetic and preparation method of composite local anesthetic injection |
| US20190038549A1 (en) * | 2017-08-07 | 2019-02-07 | Kristine Brecht | Method for performing cosmetic surgical procedures using tumescent anesthesia and oral sedation |
| CN109745101A (en) * | 2017-11-03 | 2019-05-14 | 王永红 | A method for the treatment of the compound superficial cervical plexus nerve fracture of clavicle anesthesia of brachial plexus |
| CN112120740A (en) * | 2019-06-25 | 2020-12-25 | 李文德 | Extremely-fast breast enhancement method |
-
2021
- 2021-09-14 CN CN202111084167.7A patent/CN113577072A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670489A (en) * | 2012-05-10 | 2012-09-19 | 山东洁晶药业有限公司 | Ropivacaine hydrochloride sodium chloride injection and preparation method thereof |
| CN104146954A (en) * | 2014-08-29 | 2014-11-19 | 广东埃纳生医疗投资发展有限公司 | Composite local anesthetic and preparation method of composite local anesthetic injection |
| US20190038549A1 (en) * | 2017-08-07 | 2019-02-07 | Kristine Brecht | Method for performing cosmetic surgical procedures using tumescent anesthesia and oral sedation |
| CN109745101A (en) * | 2017-11-03 | 2019-05-14 | 王永红 | A method for the treatment of the compound superficial cervical plexus nerve fracture of clavicle anesthesia of brachial plexus |
| CN112120740A (en) * | 2019-06-25 | 2020-12-25 | 李文德 | Extremely-fast breast enhancement method |
Non-Patent Citations (1)
| Title |
|---|
| 李金宝等: "《麻醉科药物速查手册》", 人民军医出版社, pages: 61 - 62 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gajraj et al. | Eutectic mixture of local anesthetics (EMLA®) cream | |
| AU2005329366A1 (en) | Reduction of postoperative pain medication | |
| CN105142625B (en) | Neosaxitonin formulated in combination product for long-lasting local anesthesia | |
| Korevaar et al. | Convulsions during stellate ganglion block: a case report | |
| KR101243519B1 (en) | Synergistic time-delaying agent for local anesthetic | |
| Breen et al. | Continuous suprascapular nerve block for analgesia of scapular fracture | |
| Chinachoti et al. | Periarticular infiltration of 0.25% bupivacaine on top of femoral nerve block and intrathecal morphine improves quality of pain control after total knee arthroplasty: a randomized double-blind placebo controlled clinical trial | |
| CN113577072A (en) | Cocktail anesthetic analgesic injection and preparation method and application thereof | |
| RU2152215C1 (en) | Use of ropivacaine in preparing pharmaceutical preparation with analgetic effect and minimal motor blockade | |
| Kvolik et al. | A wound infiltration as a method of postoperative analgesia | |
| Cobb III et al. | Intrathecal morphine for pelvic and sacral pain caused by cancer | |
| Carter et al. | Iliohypogastric nerve entrapment in pregnancy: diagnosis and treatment | |
| Connelly et al. | Continuous alfentanil infusion for extracorporeal shock wave lithotripsy of gallbladder stones | |
| Tan et al. | Femoral blockade for fractured neck of femur in the emergency department | |
| Southworth et al. | Xylocaine®: A Superior Agent for Conduction Anesthesia. | |
| Xie et al. | Clinical study of desflurane on low flow anesthesia compared with sevoflurane and enflurane | |
| Roualle | Prolonged Wound Analgesia after Surgical Operations | |
| CN104814966B (en) | A kind of intravertebral anesthesia agent and its preparation method and application | |
| RU2758755C1 (en) | Method for perioperative pain relief in the surgical treatment of varicose disease of lower extremities | |
| Edmonds-Seal et al. | Local nerve blocks for postoperative analgesia | |
| Moore et al. | Combined Brachial Block and Spinal Analgesia for Bone Graft Surgery.(Report of Eighty-Three Cases). | |
| Ræder | Regional anesthesia in ambulatory surgery | |
| CN116036288A (en) | Composition for intercostal nerve block and infiltration and injection method thereof | |
| Leonardo | Penile augmentation | |
| CN109276718A (en) | Combined closing liquid and its application containing methylthioninium chloride injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |